Awards, projects, press and partners
Each entry names the organization behind it, its date and its source, from awards to conference contributions. Peer-reviewed work is listed separately.
- The axis runs by year from 2017 to 2026.
- DESETCO, an FFG research studio, spans 2017 to 2022 as a bar.
- Two recognitions are marked in 2021: PHÖNIX, and third place at the Houska Prize as BOKU.
- ECONTI, an FFG consortium project, spans 2023 to 2025 as a bar.
- BiochAIn, three FFG Basisprogramm grants behind Novasign Studio, spans 2023 to 2025 as a bar.
- Four awards are marked in 2024: Mercur, ECONOVIUS, Staatspreis Consulting and BOKU Start-up of the Year.
- Wirtschaftszeit is marked in 2024, carrying the chief executive on that year’s prizes.
- The Repligen partnership and investment is marked in 2025, and LISAvienna’s coverage of the iCAP program beside it.
- Two 2026 publications are marked: transkript on the AAV platform project, and NurExone Biologic on applying Novasign Studio to exosome production.
- Press coverage of 30 consecutive days of full process control is marked in 2026.
Awards
- medianet, 20 June 2024WonWirtschaftskammer WienMercur Innovationspreis 2024
- APA-OTS, 7 November 2024WonWirtschaftskammer ÖsterreichECONOVIUS 2024 for the project “SmartBio”
- APA-OTS, 22 November 2024WonFederal Ministry of Labour and EconomyStaatspreis Consulting 2024 / Constantinus
- WonBOKU UniversityBOKU Start-up of the Year 2024An institutional award BOKU makes to its own spin-offs.
- OTS, 23 November 2021WonAustrian founders’ prizePHÖNIX 2021
- Third placeB&C PrivatstiftungHouska Prize 2021, third place, as BOKUAwarded to the BOKU team, not to Novasign as a company.
Projects and consortia
- 1 March 2023 – 30 April 2025FFG 4639554Coordinator enGenes Biotech, with Qubicon, SimVantage, Tosoh Bioscience and BOKUECONTI, a continuous production platform
- 2023, 2024 and 2025FFG BasisprogrammThree grants, Novasign sole beneficiaryBiochAIn, the research behind Novasign Studio
- 2017 – 2022FFG 1831170FFG Research Studios AustriaDESETCO
Press
- 30 July 2026GlobeNewswireNurExone Biologic on applying Novasign Studio to exosome production
- 13 April 2026transkriptFFG COIN next-generation AAV platform, with Holloid, enGenes and Qubicon
- April 2026GEN“30 consecutive days of full process control” on the ECONTI process
- 22 July 2025LISAviennaiCAP, continuous plasmid DNA with enGenes and Qubicon
- 3 December 2024WirtschaftszeitThe chief executive on the 2024 awards, “… schon unser zweiter Staatspreis”
- 2024ey.comListed among the “Weitere Ausgezeichnete” honoreesEY Scale-up 2024 Hall of Fame honoree listing
Partners, customers and institutions
- Investor and strategic partner, 2025
Repligen
Bioprocessing instrument vendor; investor and strategic partner since 2025.
- Automation and data
Qubicon
Continuous bioprocessing for Protein A and plasmids; the deepest connector Novasign has.
- Continuous upstream
enGenes Biotech
Continuous processing, in ECONTI and in iCAP.
- Scale-up technology
SimVantage
CFD integration for scale-up on joint projects.
- Chromatography
Tosoh Bioscience
Continuous multi-column chromatography in the ECONTI consortium.
- Downstream
Biochromatographix
Downstream and chromatography partner.
- Cell and gene therapy
Antleron
Co-development of a digital-twin approach for cell and gene therapy bioprocess development.
- Named customer
Bespark*bio
Viral-vector process characterization, published as a full case study.
- Named customer
Bisy
Komagataella phaffii upstream process optimization, published with its activity figures.
- Named customer
Rentschler
- Academic
BOKU University
The institution Novasign spun out of, and a partner on funded work.
- Research institute
ACIB
Past joint research projects.
- Education
FH Campus Wien
Teaching and training students on the platform.
Talks, posters and speaker records
- 2025PosterECONTI consortium, Duerkop among the authorsEnd-to-end continuous bioprocess automation with central data management
- 12–14 April 2023Invited talkViennaESBES HTPD2023 minisymposium, “Big Data and Modelling”
- Speaker profileInforma ConnectMark Dürkop on the BPI Europe program
In their own words
Statements Novasign’s customers and partners have published themselves.
From the beginning, bespark*bio has worked closely with Novasign… This transition is powered by Novasign Studio, which we use as our exclusive modeling environment.
We are excited to partner with Novasign, a leader in bioprocessing modelling technology.
In co-development with Novasign, we have pioneered a digital twin approach for scalable cell & gene therapy bioprocess development.
Go Novasign! The digital bioprocess tools are a reality.
Independent researchers have also written about this work in peer-reviewed papers: Boehringer Ingelheim on intensified design of experiments, Nature Communications on the BOKU-COVID19 portal. Those passages are quoted with their DOIs beside the papers.
Novasign’s own results, each with its source
Everything above was published by an awarding body, a funding agency or a journalist. The results overview lists every figure Novasign publishes, with its source.